Global Colorectal Cancer Diagnostics and Therapeutics Market - Growth, Trends & Forecast 2017 - 2022

  • ID: 4388643
  • Report
  • Region: Global
  • 205 pages
  • Mordor Intelligence
1 of 3
The global colorectal cancer diagnostics and therapeutics market is expected to grow at a CAGR of around 6% during the forecast period 2016-2021. The market is estimated to be valued at USD 8000 million in 2015 and is forecasted to reach USD 10,706 million by 2021.

The CRC pipeline is highly robust, with many potential drug candidates present across various phases of clinical development. With nearly 400 active pipeline molecules, a majority of the investigational drug candidates are being evaluated for the treatment of CRC in advanced stages, either as first-line or as second-line therapies. The current investigational pipeline candidates include new combination therapies and targeted therapies, as well as, promising immunotherapies and chemotherapy drug candidates. Along with these active progressing pipeline molecules, the pipeline also includes nearly 180 molecules that are either inactive or discontinued.

Global Colorectal Cancer Diagnostics and Therapeutics - Market Dynamics

The report details several factors driving and restraining the market, some of which are discussed below.


Technological advancements in cancer therapy

Aging population

Increasing consumer awareness


High costs of screening tests

Patent expiry of existing drugs

The global cancer diagnostics and therapeutics market has been segmented by diagnostics (fecal blood tests, flexible sigmoidoscopy, colonoscopy, virtual colonoscopy, double contrast barium enema, and others), and by therapeutics (chemotherapy, immunotherapy, and chemoprotectants). Chemotherapy has been further segmented into antimetabolites (fluorouracil and capecitabine) and alkylating agents; and immunotherapy has been further segmented into bevacizumab, cetuximab, and panitumumab. The market has been geographically segmented into North America, Europe, Asia-Pacific, and Rest of the World.

Major Companies in the Sector Include:

This Report Offers:

Market definition, along with identification of key drivers and restraints for the market.

Market analysis with region-specific assessments and competition analysis on a global and regional scale.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market share.

Identification and analysis of the macro and micro factors that affect the industry on both global and regional scale.

A comprehensive list of key market players, along with the analysis of their current strategic interests and key financial information.

An ideal source material for industry consultants, manufacturers and other interested and allied parties to gain critical insight into the factors driving and restraining the market, in addition to opportunities, offered.
Note: Product cover images may vary from those shown
2 of 3
1. Introduction
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Research Methodology
2. Market definition
3. Executive summary
4. Market overview
4.1 Market drivers
4.1.1 Technological Advancements in Radiology and Chemotherapy
4.1.2 Aging Population
4.1.3 Increasing Consumer Awareness
4.2 Market restraints
4.2.1 Expiry of Drug Patents
4.2.2 Screening test costs
4.3 Market opportunities
4.3.1 Highly Robust Product Pipeline
4.4 Market Challenges
4.4.1 Less Awareness and Practice of Cancer Screening Tests in Developing Countries
5. Porters five force analysis
5.1 Bargaining power of suppliers
5.2 Bargaining power of buyers
5.3 Degree of comprtition
5.4 Threat of substitution
5.5 Threat of new entrants
6. Market segmentation
6.1 By Diagnostics
6.1.1 Digital Rectal Examination
6.1.2 Fecal Occult Blood Test
6.1.3 Flexible Sigmoidoscopy
6.1.4 Colonoscopy
6.1.5 Virtual Colonoscopy
6.1.6 Double Contrast Barium Enema
6.1.7 Others
6.2 By Therapeutics
6.2.1 Chemotherapy Antimetabolites Fluorouracil Capecitabine Alkylating Agent
6.2.2 Immunotherapy Monoclonal Antibodies Bevacizumab Cetuximab Panitumumab
6.2.3 Chemoprotectant
6.3 By geography
6.3.1 North America United States Canada Mexico
6.3.2 Europe France Germany Italy Spain United Kingdom Rest of Europe
6.3.3 Asia-Pacific China India Japan Korea Singapore Rest of APAC
6.3.4 Rest of the world
7. Competitive Landscape
7.1 Mergers & Acquisitions
7.2 Agreements, Partnerships and Collaborations
7.3 New Product Launches
8. Company profiles
8.1 Abbott Diagnostics
8.2 Alere
8.3 Beckman Coulter
8.4 Clinical Genomics
8.5 Companion Dx
8.6 EDP Biotech
8.7 Epigenomics AG
8.8 Exact Sciences
8.9 Fujirebio (Miraca Holdings)
8.10 Genomic Tree
8.11 Metabiomics Corporation
8.12 Oncocyte (Biotime)
8.13 Quest Diagnostics
8.14 Randox Laboratories
8.15 Siemens Healthcare
8.16 Volition Rx
9. Appendix
9.1 Abbreviations
9.2 Sources
9.3 Bibliography
9.4 Disclaimer
Note: Product cover images may vary from those shown
3 of 3


4 of 3
Note: Product cover images may vary from those shown